Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC -0.27%91 EV-to-FCF is 156.74 as of Jul. 15, 2026, which is 823% above its 10-year median of 16.98. GuruFocus rates XPAE:BPC with a GF Score™ of 91/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 564 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks worse than 90.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Birzeit Pharmaceutical Co's Enterprise Value is $139.50 Mil.
Birzeit Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $0.89 Mil. Therefore, Birzeit Pharmaceutical Co's EV-to-FCF for today is 156.74.
The historical rank and industry rank for Birzeit Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
XPAE:BPC'
s EV-to-FCF Range Over the Past 10 Years
Min: -400.14 Med: 16.98 Max: 56153.42
Current: 158.05
During the past 13 years, the highest EV-to-FCF of Birzeit Pharmaceutical Co was 56153.42. The lowest was -400.14. And the median was 16.98.
XPAE:BPC's EV-to-FCF is ranked worse than 90.78% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs XPAE:BPC: 158.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Birzeit Pharmaceutical Co (XPAE:BPC) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Birzeit Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Birzeit Pharmaceutical Co's share price for today is $3.67.
Birzeit Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.324.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Birzeit Pharmaceutical Co EV-to-FCF Related Terms
Birzeit Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's EV-to-FCF falls into.
Birzeit Pharmaceutical Co's current Enterprise Value is $139.50 Mil.
Birzeit Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a EV-to-FCF of 156.74 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Birzeit Pharmaceutical Co and its competitors. This is 823% above median its historical median of 16.98. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #512 out of 564 companies in the Drug Manufacturers industry, placing it in the top 90.8%.
Is Birzeit Pharmaceutical Co's EV-to-FCF too high?
Birzeit Pharmaceutical Co's current EV-to-FCF of 156.74 is 823% above median its 10-year median of 16.98. The Drug Manufacturers industry median EV-to-FCF is 20.90. Birzeit Pharmaceutical Co's value of 156.74 is 650.1% above this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #512 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #512 out of 564 companies for EV-to-FCF. This places Birzeit Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 20.90. Birzeit Pharmaceutical Co's value of 156.74 is 650.1% above this benchmark. While the company's 10-year median is 16.98 vs. the industry median of 20.90, Birzeit Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current EV-to-FCF of 156.74 is 650.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current EV-to-FCF is 156.74, which is 823% above median its own 10-year median of 16.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current EV-to-FCF is 156.74, which is 823% above median its 10-year median of 16.98 and 650.1% above the Drug Manufacturers industry median of 20.90. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current EV-to-FCF is 156.74 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
EV-to-FCF: 156.74 (823% above median its 10-year median of 16.98)
GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
Industry Position: 650.1% above the Drug Manufacturers median (#512 of 564)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score
Get the complete analysis for XPAE:BPC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
